Nomegestrol acetate
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Nomegestrol acetate
- DrugBank Accession Number
- DB13981
- Background
Nomegestrol acetate, also known as NOMAC, is a progestin used in oral contraceptives, menopausal hormone therapy, and for the treatment of gynecological disorders.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Nomegestrol acetate (DB13981)
- Weight
- Average: 370.489
Monoisotopic: 370.214409446 - Chemical Formula
- C23H30O4
- Synonyms
- 17-alpha-Acetoxy-6-methyl-19-nor-4,6-pregnadiene-3,20-dione
- 17-alpha-Hydroxy-6-methyl-19-norpregna-4,6-diene-3,20-dione acetate
- Nomegestrol acetate
- External IDs
- ORG 10486-0
- ORG-10486-0
- TX 066
- TX-066
Pharmacology
- Indication
Not Available
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbametapir The serum concentration of Nomegestrol acetate can be increased when it is combined with Abametapir. Abciximab The risk or severity of adverse effects can be increased when Nomegestrol acetate is combined with Abciximab. Acenocoumarol The risk or severity of adverse effects can be increased when Nomegestrol acetate is combined with Acenocoumarol. Acetaminophen The metabolism of Nomegestrol acetate can be increased when combined with Acetaminophen. Acetazolamide The metabolism of Nomegestrol acetate can be increased when combined with Acetazolamide. Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Nomegestrol acetate. Acitretin The therapeutic efficacy of Nomegestrol acetate can be decreased when used in combination with Acitretin. Alitretinoin The therapeutic efficacy of Nomegestrol acetate can be decreased when used in combination with Alitretinoin. Alpelisib The metabolism of Nomegestrol acetate can be increased when combined with Alpelisib. Alteplase The risk or severity of adverse effects can be increased when Nomegestrol acetate is combined with Alteplase. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image FEMIDEN® 1.5 MG/2.5MG TABLETAS RECUBIERTAS Nomegestrol acetate (2.5 mg) + Estradiol hemihydrate (1.5 mg) Tablet, coated Oral 2019-02-27 Not applicable Colombia 
OBLAISE ® Nomegestrol acetate (2.5 mg) + Estradiol hemihydrate (1.5 mg) Tablet, coated Oral 2016-12-28 Not applicable Colombia Zoely Nomegestrol acetate (2.5 mg) + Estradiol hemihydrate (1.5 mg) Tablet, film coated Oral Theramex Ireland Limited 2016-09-08 Not applicable EU 
Zoely Nomegestrol acetate (2.5 mg) + Estradiol hemihydrate (1.5 mg) Tablet, film coated Oral Theramex Ireland Limited 2016-09-08 Not applicable EU Zoely Nomegestrol acetate (2.5 mg) + Estradiol hemihydrate (1.5 mg) Tablet, film coated Oral Theramex Ireland Limited 2016-09-08 Not applicable EU Zoely Nomegestrol acetate (2.5 mg) + Estradiol hemihydrate (1.5 mg) Tablet, film coated Oral Theramex Ireland Limited 2016-09-08 Not applicable EU ZOELY (2.5 MG/1.5 MG FILM-COATED TABLETS) Nomegestrol acetate (2.5 MG) + Estradiol (1.5 MG) Tablet, film coated Oral บริษัท เอ็มเอสดี (ประเทศไทย) จำกัด 2018-05-02 Not applicable Thailand 
Categories
- Drug Categories
- Adrenal Cortex Hormones
- Antineoplastic Agents, Hormonal
- Combination Contraceptives (with Estrogen and derivatives)
- Contraceptive Agents, Female
- Contraceptives, Oral
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Substrates
- Fused-Ring Compounds
- Hormonal Contraceptives for Systemic Use
- Norpregnanes
- Norsteroids
- Pregnadienes
- Pregnanes
- Progesterone Congeners
- Progestin Contraceptives
- Progestins
- Steroids
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Pregnane steroids
- Direct Parent
- Gluco/mineralocorticoids, progestogins and derivatives
- Alternative Parents
- Steroid esters / 20-oxosteroids / 3-oxosteroids / Cyclohexenones / Alpha-acyloxy ketones / Carboxylic acid esters / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives
- Substituents
- 20-oxosteroid / 3-oxosteroid / Aliphatic homopolycyclic compound / Alpha-acyloxy ketone / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Cyclic ketone / Cyclohexenone / Hydrocarbon derivative
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 83J78V5W05
- CAS number
- 58652-20-3
- InChI Key
- IIVBFTNIGYRNQY-YQLZSBIMSA-N
- InChI
- InChI=1S/C23H30O4/c1-13-11-20-18(17-6-5-16(26)12-19(13)17)7-9-22(4)21(20)8-10-23(22,14(2)24)27-15(3)25/h11-12,17-18,20-21H,5-10H2,1-4H3/t17-,18-,20-,21+,22+,23+/m1/s1
- IUPAC Name
- (1R,3aS,3bS,9aR,9bS,11aS)-1-acetyl-5,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl acetate
- SMILES
- [H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C(C)=C[C@@]21[H]
References
- General References
- External Links
- KEGG Drug
- D08281
- ChemSpider
- 82771
- 53744
- ChEBI
- 135564
- ChEMBL
- CHEMBL1476022
- ZINC
- ZINC000003938628
- Wikipedia
- Nomegestrol_acetate
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Other Ovulation Inhibition 1 4 Terminated Screening Contraception / Hypercoagulability 1 4 Unknown Status Treatment Hypermenorrhea 1 3 Completed Prevention Contraception 1 3 Terminated Prevention Contraception 1 3 Unknown Status Treatment Disseminated Sclerosis 1 3 Withdrawn Treatment Contraception 1 2 Completed Treatment Contraception 1 2 Completed Treatment Menstrual Cramps 1 1 Completed Not Available Contraception 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral Tablet Oral 5 MG Tablet Oral Tablet, coated Oral Tablet, film coated Oral Tablet, film coated Oral 2.5 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00415 mg/mL ALOGPS logP 3.46 ALOGPS logP 3.42 ChemAxon logS -5 ALOGPS pKa (Strongest Acidic) 17.72 ChemAxon pKa (Strongest Basic) -4.8 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 60.44 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 104.18 m3·mol-1 ChemAxon Polarizability 41.78 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Binkowska M, Woron J: Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015 Jun;14(2):134-43. doi: 10.5114/pm.2015.52154. Epub 2015 Jun 22. [Article]
Drug created on January 20, 2018 15:25 / Updated on February 21, 2021 18:54